{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Macular+Edema%2C+Diabetic&page=5",
    "query": {
      "condition": "Macular Edema, Diabetic",
      "page": 5
    },
    "page_size": 10
  },
  "pagination": {
    "page": 5,
    "page_size": 10,
    "total_count": 294,
    "total_pages": 30,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Macular+Edema%2C+Diabetic&page=6&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Macular+Edema%2C+Diabetic&page=4&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-10T17:11:39.860Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01304706",
      "title": "Fluocinolone Acetonide in Diabetic Macular Edema (FAME) Extension Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetic Macular Edema"
      ],
      "interventions": [
        {
          "name": "Fluocinolone Acetonide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alimera Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 120,
      "start_date": "2011-04",
      "completion_date": null,
      "has_results": true,
      "last_update_posted_date": "2015-05-04",
      "last_synced_at": "2026-10-10T17:11:39.860Z",
      "location_count": 1,
      "location_summary": "Alpharetta, Georgia",
      "locations": [
        {
          "city": "Alpharetta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01304706"
    },
    {
      "nct_id": "NCT02000102",
      "title": "Outcomes of Diabetic Macula Edema Patients Switched to Aflibercept From Bevacizumab and/or Ranibizumab",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Diabetic Macular Edema"
      ],
      "interventions": [
        {
          "name": "Intravitreal Injection of Aflibercept",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2013-09",
      "completion_date": "2014-09",
      "has_results": false,
      "last_update_posted_date": "2014-11-18",
      "last_synced_at": "2026-10-10T17:11:39.860Z",
      "location_count": 1,
      "location_summary": "Palo Alto, California",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02000102"
    },
    {
      "nct_id": "NCT05919693",
      "title": "A 2-part Study Consisting of Multiple Ascending Dose (MAD) Safety Study, and a Dose-finding Masked Study to Assess the Safety and Efficacy of Intravitreal (IVT) EYE103 in Patients With Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (NVAMD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Neovascular Age-related Macular Degeneration (NVAMD)",
        "Diabetic Macular Edema (DME)"
      ],
      "interventions": [
        {
          "name": "EYE103",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "EyeBiotech Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 33,
      "start_date": "2023-06-12",
      "completion_date": "2024-08-26",
      "has_results": true,
      "last_update_posted_date": "2026-09-29",
      "last_synced_at": "2026-10-10T17:11:39.860Z",
      "location_count": 27,
      "location_summary": "Phoenix, Arizona • Bakersfield, California • Modesto, California + 23 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Modesto",
          "state": "California"
        },
        {
          "city": "Mountain View",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05919693"
    },
    {
      "nct_id": "NCT07484074",
      "title": "A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of Intravitreal OLN324",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diabetic Macular Edema (DME)",
        "Neovascular (Wet) Age-Related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "Faricimab",
          "type": "DRUG"
        },
        {
          "name": "OLN324",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ollin Biosciences, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 164,
      "start_date": "2025-02-12",
      "completion_date": "2025-12-09",
      "has_results": false,
      "last_update_posted_date": "2026-03-19",
      "last_synced_at": "2026-10-10T17:11:39.860Z",
      "location_count": 29,
      "location_summary": "Phoenix, Arizona • Glendale, California • Pasadena, California + 26 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Pasadena",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Walnut Creek",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07484074"
    },
    {
      "nct_id": "NCT03610646",
      "title": "Comparative Study to Evaluate the Efficacy and Safety of MYL-1701P and Eylea® in Subjects With Diabetic Macular Edema (DME)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetic Macular Edema"
      ],
      "interventions": [
        {
          "name": "MYL-1701P",
          "type": "DRUG"
        },
        {
          "name": "Eylea",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mylan Pharmaceuticals Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 355,
      "start_date": "2018-08-23",
      "completion_date": "2021-09-10",
      "has_results": true,
      "last_update_posted_date": "2023-03-07",
      "last_synced_at": "2026-10-10T17:11:39.860Z",
      "location_count": 13,
      "location_summary": "Phoenix, Arizona • Sacramento, California • St. Petersburg, Florida + 9 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        },
        {
          "city": "Winter Haven",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03610646"
    },
    {
      "nct_id": "NCT05698329",
      "title": "Effect of AIV007 by Periocular Administration in Subjects with Macular Edema Secondary to Neovascular Age-related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neovascular Age-related Macular Degeneration",
        "Diabetic Macular Edema",
        "Macular Edema"
      ],
      "interventions": [
        {
          "name": "AIV007",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AiViva BioPharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "21 Years to 90 Years"
      },
      "enrollment_count": 19,
      "start_date": "2023-03-02",
      "completion_date": "2025-04-01",
      "has_results": false,
      "last_update_posted_date": "2025-03-06",
      "last_synced_at": "2026-10-10T17:11:39.860Z",
      "location_count": 6,
      "location_summary": "Beverly Hills, California • Santa Ana, California • Eugene, Oregon + 3 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Santa Ana",
          "state": "California"
        },
        {
          "city": "Eugene",
          "state": "Oregon"
        },
        {
          "city": "McAllen",
          "state": "Texas"
        },
        {
          "city": "Plano",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05698329"
    },
    {
      "nct_id": "NCT05569148",
      "title": "A Study in Patients With Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema to Evaluate the Safety of the Faricimab Prefilled Syringe",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Neovascular Age-related Macular Degeneration",
        "Diabetic Macular Edema"
      ],
      "interventions": [
        {
          "name": "Faricimab PFS Configuration",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 35,
      "start_date": "2022-10-17",
      "completion_date": "2022-11-10",
      "has_results": true,
      "last_update_posted_date": "2023-10-10",
      "last_synced_at": "2026-10-10T17:11:39.860Z",
      "location_count": 3,
      "location_summary": "Mesa, Arizona • Phoenix, Arizona",
      "locations": [
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05569148"
    },
    {
      "nct_id": "NCT01168258",
      "title": "Evaluation of Single Nucleotide Polymorphisms (SNPs) in Patients With and Without Diabetic Macular Edema",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Diabetic Retinopathy",
        "Diabetic Macular Edema"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Eye Institute (NEI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 68,
      "start_date": "2010-07-07",
      "completion_date": "2013-08-07",
      "has_results": false,
      "last_update_posted_date": "2017-10-06",
      "last_synced_at": "2026-10-10T17:11:39.860Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01168258"
    },
    {
      "nct_id": "NCT02712008",
      "title": "Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetic Macular Edema"
      ],
      "interventions": [
        {
          "name": "REGN910-3",
          "type": "DRUG"
        },
        {
          "name": "Intravitreal Aflibercept Injection (IAI)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 302,
      "start_date": "2016-03-02",
      "completion_date": "2017-07-10",
      "has_results": true,
      "last_update_posted_date": "2018-10-03",
      "last_synced_at": "2026-10-10T17:11:39.860Z",
      "location_count": 51,
      "location_summary": "Mesa, Arizona • Tucson, Arizona • Arcadia, California + 48 more",
      "locations": [
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Arcadia",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Mountain View",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02712008"
    },
    {
      "nct_id": "NCT07456826",
      "title": "Study Evaluating the Efficacy and Safety of Chloroprocaine HCl Ophthalmic Gel 3% vs Proparacaine Ophthalmic Solution 0.5% Plus Subconjunctival Lidocaine in Patients Undergoing Intravitreal Injections",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Diabetic Macular Edema (DME)",
        "Age-Related Macular Degeneration (AMD)",
        "Retinal Vein Occlusion",
        "Diabetic Retinopathy (DR)"
      ],
      "interventions": [
        {
          "name": "Chloroprocaine Ophthalmic Gel 3% (IHEEZO)",
          "type": "DRUG"
        },
        {
          "name": "Sham Subconjunctival Injection",
          "type": "PROCEDURE"
        },
        {
          "name": "Proparacaine Hydrochloride Ophthalmic Solution 0.5%",
          "type": "DRUG"
        },
        {
          "name": "Lidocaine Hydrochloride Injection 2%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Harrow Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 236,
      "start_date": "2026-03-31",
      "completion_date": "2026-08",
      "has_results": false,
      "last_update_posted_date": "2026-04-07",
      "last_synced_at": "2026-10-10T17:11:39.860Z",
      "location_count": 1,
      "location_summary": "Tyler, Texas",
      "locations": [
        {
          "city": "Tyler",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07456826"
    }
  ]
}